Clinical trial • Phase I • Immunology
LAD106 for Inflammatory diseases
Phase I trial of LAD106 for Inflammatory diseases. 93 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Inflammatory diseases
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 08-12-2025
- First CTIS Authorization Date
- 06-02-2026
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 93
Recruitment
- Planned Sample Size
- 93
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 93
Netherlands
- Earliest CTIS Part Ii Submission Date
- 03-02-2026
- Latest Decision Or Authorization Date
- 06-02-2026
- Processing Time Days
- 3
- Number Of Sites
- 1
- Number Of Participants
- 93
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Dermatology
- Contact Person Name
- Robert Rissmann
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Almirall S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- LAD106
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis